Regulatory Credentials

BioBlend Compounding Pharmacy operates under the regulatory framework of the United Arab Emirates. This page sets out our licensing, accreditation standards and quality commitments, consistent with the Ministry of Health and Prevention (MOHAP), the Dubai Health Authority (DHA) and the Emirates Health Establishment (EDE) framework.

1. Pharmacy Licence

1. BioBlend Compounding Pharmacy is a licensed pharmaceutical facility operating in Dubai, United Arab Emirates.
2. Our facility is licensed to compound pharmaceutical products on the basis of a valid prescription and to supply compounded products to health facilities and patients as required.
3. Licence number and issuing authority are made available to regulatory inspectors and, where appropriate, to patients on request.

2. Standards We Are Committed To

Our compounding and quality processes are designed to follow:

1. Ministry of Health and Prevention (MOHAP) Guidelines — the national framework for pharmacy and compounding practice in the UAE.
2. Good Compounding Practice (GCP), MOHAP, UAE — the documented practice standard for compounding in the Emirates.
3. United States Pharmacopoeia (USP) Guidelines — including USP <797> for sterile preparations and USP <795> for non-sterile preparations.
4. Accreditation Commission for Health Care (ACHC) — Pharmacy Compounding Accreditation Board (PCAB) Standards — an internationally recognised symbol of quality in healthcare compounding.
5. cGMP-sourced pharmaceutical-grade ingredients — from suppliers inspected to current Good Manufacturing Practice standards.

3. Accreditation & Quality

1. ACHC accreditation represents independent verification of a provider's compliance with quality standards, recognised as a mark of excellence in healthcare.
2. We follow up-to-date international standards to help ensure excellence for our patients, using quality ingredients and the latest equipment.
3. Our internal quality system covers master formulas, batch records, release checks, certificate of analysis and traceability.

4. Sensitive & Sterile Compounding

1. Sterile preparations (IV infusions, injectable peptides, parenteral nutrition) are prepared under aseptic conditions consistent with USP <797>.
2. Non-sterile preparations are compounded following USP <795> principles and MOHAP Good Compounding Practice.
3. Each sterile batch is subject to documented quality verification before release.

5. Cold-Chain Integrity

1. Cold-chain products are stored, packed and transported at 2–8°C with monitored packaging.
2. Temperature integrity is maintained from the pharmacy to the patient across supported delivery zones.
3. Documentation is available on request to support regulatory and patient assurance.

6. Traceability & Recall Readiness

1. Every compounded batch carries a lot number, preparation record and certificate of analysis for traceability.
2. Our records are structured to support rapid identification of affected lots if recall is required.
3. We participate in pharmacovigilance and adverse-event reporting consistent with MOHAP, DHA and EDE obligations.

7. DHA Compliance (Dubai)

1. Where our activities are licensed by the Dubai Health Authority we comply with DHA pharmacy, patient-confidentiality and data-handling requirements.
2. We support DHA inspections and provide records on request within the scope of our licence.

8. EDE Framework

1. As part of the Emirates health establishment framework our operations align with national health-system requirements for licensed pharmacies.
2. We coordinate with the relevant health establishment bodies where required to ensure continuity of safe supply.

9. Controlled & Regulated Items

1. Controlled and prescription items are dispensed only against a valid prescription following pharmacist review.
2. Quantities, refills and eligibility are governed by UAE law and the relevant health authority.
3. We do not supply research-grade or grey-market materials under any circumstance.

10. Verification & Transparency

1. Our pharmacists' verification status and licence authorities may be displayed on published profiles.
2. Patients and regulators may request verification of our credentials; some records are shared only with authorised regulators.
3. We are committed to transparent, accurate disclosure of our regulatory standing to the extent permitted by UAE law.

11. Continuous Improvement

1. We review our procedures and documentation regularly against updates to MOHAP, DHA, EDE and USP standards.
2. We invest in equipment, training and document control to keep pace with international compounding practice.
3. Our compliance functions support audit readiness throughout the year.

12. Contact & Verification Requests

For verification requests, regulatory correspondence or complaints, contact:

BioBlend Compounding Pharmacy Wasl Sports Club Shops, Al Nawras Street, Al Jaddaf PO Box 33233, Dubai, United Arab Emirates Phone: +971 4 222 2500 Email: hello@bioblend.ae

This page summarises our regulatory commitments. Specific licence and accreditation details are updated as records are verified, and are available to regulators and (on request) to patients within the limits of UAE law.